Review
. 2006 Mar-Apr;25(2):140-5; quiz 146-7.
doi: 10.1097/00006416-200603000-00013.
The pathogenesis of systemic lupus erythematosus
- PMID: 16572034
- DOI: 10.1097/00006416-200603000-00013
Item in Clipboard
Review
The pathogenesis of systemic lupus erythematosus
Orthop Nurs.
2006 Mar-Apr.
Abstract
Systemic lupus erythematosus is an autoimmune disease that causes inflammation in the tissues of the brain, endothelial cells, gastrointestinal/genitourinary (GI/GU), joints, kidneys, muscles, and skin. Lupus comprises a range of multisystem disorders involving the deposition of aberrant immune complexes into tissues. Inflammation occurs as a result of autoantibodies attacking organ systems. The pathogenesis of systemic lupus erythematosus is presented.
Similar articles
-
New insights into the immunopathogenesis of systemic lupus erythematosus.Nat Rev Rheumatol. 2016 Nov 22;12(12):716-730. doi: 10.1038/nrrheum.2016.186. Nat Rev Rheumatol. 2016. PMID: 27872476 Review.
-
Systemic lupus erythematosus sera inhibit antigen presentation by macrophages to T cells.Clin Immunol Immunopathol. 1988 Feb;46(2):299-313. doi: 10.1016/0090-1229(88)90192-4. Clin Immunol Immunopathol. 1988. PMID: 3257427
-
Expanding the B Cell-Centric View of Systemic Lupus Erythematosus.Trends Immunol. 2017 May;38(5):373-382. doi: 10.1016/j.it.2017.02.001. Epub 2017 Mar 6. Trends Immunol. 2017. PMID: 28274696 Free PMC article. Review.
-
Genetic and immunological mechanisms in the pathogenesis of systemic lupus erythematosus.Curr Opin Immunol. 1992 Dec;4(6):733-40. doi: 10.1016/0952-7915(92)90054-i. Curr Opin Immunol. 1992. PMID: 1281640 Review.
-
Systemic lupus erythematosus.Sci Am. 1980 Jul;243(1):40-9. Sci Am. 1980. PMID: 6450445 No abstract available.
Cited by
-
Human monoclonal antibodies targeting nonoverlapping epitopes on insulin-like growth factor II as a novel type of candidate cancer therapeutics.Mol Cancer Ther. 2012 Jul;11(7):1400-10. doi: 10.1158/1535-7163.MCT-12-0172. Epub 2012 May 2. Mol Cancer Ther. 2012. PMID: 22553356 Free PMC article.
-
An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus.Lupus. 2009 May;18(6):547-55. doi: 10.1177/0961203309102803. Lupus. 2009. PMID: 19395457 Free PMC article. Clinical Trial.
-
Adverse event burden, resource use, and costs associated with immunosuppressant medications for the treatment of systemic lupus erythematosus: a systematic literature review.Int J Rheumatol. 2013;2013:347520. doi: 10.1155/2013/347520. Epub 2013 Apr 3. Int J Rheumatol. 2013. PMID: 23762067 Free PMC article.
-
Immune mechanism: a 'double-edged sword'.Malays J Med Sci. 2013 May;20(3):61-7. Malays J Med Sci. 2013. PMID: 23966827 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
